Extended-release trazodone in the treatment of major depressive disorder


Karamustafalioglu O., Dilbaz N., Caykoylu A., Alkin T., GÖNÜL A. S. , Atmaca M.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, cilt.20, ss.453-459, 2019 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 20 Konu: 5
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5455/apd.302644467
  • Dergi Adı: ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY
  • Sayfa Sayısı: ss.453-459

Özet

Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.